Custom Pharmaceuticals launches new company for drug product development
Charlie Blackie-Kelly | November 12, 2025 | News story | Business Services | Centrix Pharma Solutions, Company Launch, Custom Pharmaceuticals, collaboration, drug development, university of sussex
Customs Pharmaceuticals, a full-service contract development and manufacturing organisation (CDMO), has launched Centrix Pharma Solutions, a new company targeting faster drug and drug product development timelines through collaborative partnerships.
Centrix, headquartered in Hove, East Sussex, will operate from a laboratory on the University of Sussex campus, leveraging the University’s research expertise and talent pipeline to help translate scientific innovations into real-world therapeutic applications.
As part of its launch, Centrix has entered an integrated chemistry, manufacturing, and control (CMC) partnership with Sai Life Sciences and Agility Life Sciences. The collaboration aims to expand Centrix’s capabilities in supporting biopharma companies, including optimising routes from preclinical studies to first-in-human trials.
Custom Pharmaceuticals will work alongside Centrix and other contract manufacturing organisations (CMOs) to deliver high-quality pharmaceutical products and build efficient pathways to market. Centrix is targeting 50% year-on-year growth over the next two years, backed by an £850,000 investment in advanced manufacturing and formulation equipment.
Chris Davison, CEO of Custom Pharmaceuticals and Centrix Pharma Solutions, said: “Launching Centrix marks a bold new chapter for us. We’ve evolved from packaging to manufacturing, and now we’re stepping up as an innovation partner in drug product development. Being based at the University of Sussex allows us to spark collaboration, blending our know-how with academic research and the energy of future scientists. Together, we’re pushing forward the ideas that will shape tomorrow’s medicines.”
Related Content
EVerZom enters research and licensing agreement with GENFIT
EVerZom, a French biotech company developing exosome-based therapies for regenerative medicine, has entered into a …
BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …
BioDuro and Silicogenix collaborate to advance non-traditional drug development
BioDuro, a contract research, development and manufacturing organisation, has announced a strategic partnership with small …
